Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Chuikyo at Odds over Handling of Startups in PMP, Timing of Deferred Price Cuts
October 19, 2023
- Medipharma Might Face Administrative Penalty over Trial Data Tampering
October 18, 2023
- Average Price Gap for 2024 Revision Looks to Be Lower than 7.0%: Wholesalers
October 18, 2023
- AMED Group to Draft Master Protocols Guidelines by March-End, Frets Further Drug Lag/Loss
October 17, 2023
- MHLW Sets Up Hotline for Production Site Change for Supply-Crippled Drugs
October 17, 2023
- Health Minister Laments Drug Lag/Loss, Stresses Need for Govt-Driven Innovation Ecosystem
October 16, 2023
- MHLW Regulatory Panel OKs New Procedures for Post-Approval Manufacturing Changes
October 16, 2023
- Japan’s New Economic Package to Include Dementia Measures: PM
October 16, 2023
- Xarelto’s Label Expansion Up for Japan Panel Review on Oct. 27
October 16, 2023
- MHLW to Swiftly Deliberate Additional Purchase of COVID Jabs: Minister
October 16, 2023
- Label Revisions Ordered for G-CSF Agents, Yervoy and More
October 13, 2023
- MHLW Preparatory Council Boots Up for Japan-Version of CDC
October 13, 2023
- MHLW Panel Proposes Assessing Generic Makers’ Efforts toward Stable Supplies, Reflecting Results in Pricing
October 12, 2023
- Drug Innovation Measures Likely to Be Embraced in Govt Economic Package
October 12, 2023
- Vyvgart, Dysval Braced for Price Cuts after CEA, No Change for Ondexxya
October 12, 2023
- MHLW Pondering Every Possible Avenue to Supply Cough Drugs: Minister
October 11, 2023
- MHLW Set to Submit Bill to Lift Ban on Cannabis-Derived Drugs
October 11, 2023
- Japan Panel to Review Label Expansions for Opdivo, Adcetris, and More on Oct. 23
October 10, 2023
- Many Back Expansion in Range of CEA Price Tweaks for Pricey Drugs: Chuikyo
October 5, 2023
- Post-Launch Re-Pricing Likely the Focus of Chuikyo Leqembi Discussions
October 5, 2023
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…